MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/jc.2016-3628

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2017

Effects of Metreleptin in Pediatric Patients With Lipodystrophy.

Brown Rebecca J, Meehan Cristina Adelia, Cochran Elaine, Rother Kristina I, Kleiner David E, Walter Mary, Gorden Phillip

СтатьяResearch Support, N.I.H., IntramuralПеревод в очереди

Аннотация

CONTEXT: Lipodystrophy syndromes are rare disorders of deficient adipose tissue. Metreleptin, a human analog of leptin, improved metabolic abnormalities in mixed cohorts of children and adults with lipodystrophy and low leptin.

OBJECTIVE

Determine effects of metreleptin on diabetes, hyperlipidemia, nonalcoholic fatty liver disease (NAFLD), growth, and puberty in pediatric patients with lipodystrophy and low leptin.

DESIGN

Prospective, single-arm, open-label studies with continuous enrollment since 2000.

SETTING

National Institutes of Health, Bethesda, Maryland.

PATIENTS: Fifty-three patients aged 6 months to <18 years with lipodystrophy, leptin level <8 ng/mL (male patients) or <12 ng/mL (female patients), and ≥1 metabolic abnormality (diabetes, insulin resistance, or hypertriglyceridemia).

INTERVENTION: Subcutaneous metreleptin injections (0.04 to 0.19 mg/kg/d).

MAIN OUTCOME MEASURES: Change in A1c, lipid, and transaminase levels after a mean ± standard deviation (SD) of 12 ± 0.2 months and 61 ± 39 months. Changes in liver histology, growth, and pubertal development throughout treatment.

RESULTS

After 12 months, the A1c level (mean ± SD) decreased from 8.3% ± 2.4% to 6.5% ± 1.8%, and median triglyceride level decreased from 374 mg/dL [geometric mean (25th,75th percentile), 190, 1065] to 189 mg/dL (112, 334; P < 0.0001), despite decreased glucose- and lipid-lowering medications. The median [geometric mean (25th,75th percentile)] alanine aminotransferase level decreased from 73 U/L (45, 126) to 41 U/L (25, 59; P = 0.001), and that of aspartate aminotransferase decreased from 51 U/L (29, 90) to 26 U/L (18, 42; P = 0.0002). These improvements were maintained over long-term treatment. In 17 patients who underwent paired biopsies, the NAFLD activity score (mean ± SD) decreased from 4.5 ± 2.0 to 3.4 ± 2.0 after 3.3 ± 3.2 years of metreleptin therapy (P = 0.03). There were no clinically significant changes in growth or puberty.

CONCLUSION

Metreleptin lowered A1c and triglyceride levels, and improved biomarkers of NAFLD in pediatric patients with lipodystrophy. These improvements are likely to reduce the lifetime burden of disease.

Для цитирования: Brown Rebecca J, Meehan Cristina Adelia, Cochran Elaine, Rother Kristina I, Kleiner David E, Walter Mary, Gorden Phillip. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.. The Journal of clinical endocrinology and metabolism. 2017. DOI: 10.1210/jc.2016-3628.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.